We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


ASCT-related toxicities for patients with MCL

Tuesday, August 8, 2017

Peter Martin, M.D., assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medicine, spoke to OncLive about the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).

It is becoming easier for practitioners to help these patients through an autologous stem cell transplant procedure, Martin explains. Nonetheless, there is still associated fatigue and a risk of infection, but practitioners are also improving at controlling those infections.

As patients get older, those infections can have more of an impact. There is a small but significant risk of secondary neoplasm myelodysplastic syndrome acute myeloid leukemia that appears to be related to cumulative exposure to chemotherapy, he adds.